SCHEMBL116925

SCHEMBL116925

CC(=O)C1=C(c2ccccc2)c2ccccc2C1=O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.86
HSP90AB1 P08238 3/20 0.86
FGFR1 P11362 9/20 0.73
FGFR2 P21802 9/20 0.73
FGFR4 P22455 9/20 0.73
FGFR3 P22607 9/20 0.73
SRC P12931 6/20 0.69
CRHBP P24387 1/20 0.69
CRHR2 Q13324 1/20 0.69
NPSR1 Q6W5P4 3/20 0.66
MEN1 O00255 2/20 0.66
LMNA P02545 2/20 0.66
XBP1 P17861 2/20 0.66
KMT2A Q03164 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
MAPT P10636 2/20 0.66
HTT P42858 2/20 0.66
KDM4E B2RXH2 1/20 0.66
NPC1 O15118 1/20 0.66
MAPK1 P28482 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17969802 0.93 HSP90AA1 (1.00) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL147279 0.85 FGFR1 (1.00) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL116862 0.82 FGFR1 (0.73) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL144665 0.81 FGFR1 (1.00) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL143675 0.81 FGFR1 (1.00) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL14231952 0.77 FGFR1 (0.77) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL7538581 0.77 PPARG (0.72) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL13770821 0.77 FGFR1 (0.85) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL17969803 0.75 HSP90AA1 (0.70) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4
SCHEMBL9178962 0.75 APAF1 (0.60) HSP90AA1HSP90AB1FGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 HSP90AA1 514/4885HSP90AB1 353/4885FGFR1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.